Drug Trial Radar · NCT05042206
Phase 1 Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Nov 24, 2021
Primary completion
Sep 21, 2023
Study completion Sep 21, 2023
Sponsor
- Lead sponsor
- Pharmicell Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety of Cellgram-CKD in patients with chronic kidney disease over 12 months after three administrations. The main question it aims to answer is: \- What medical problems do participants have after receiving Cellgram-CKD? Participants will: \- Receive Cellgram-CKD by intravenous infusion three times at 2-week intervals. Visit the clinic 1, 3, 6, 9, and 12 months after the third administration for safety assessments.
Conditions
- Chronic Kidney Disease
Interventions
Cellgram-CKDBiological
5 × 10\^7 allogeneic bone marrow-derived mesenchymal stem cells (10 mL) administered by intravenous infusion three times at 2-week (14-day) intervals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: From the first administration of the investigational product to 12 months after the third administration of the investigational product.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.